Quantcast
Home > Quotes > RIGL
RIGL

Rigel Pharmaceuticals, Inc. Common Stock (RIGL) Quote & Summary Data

$2.67
*  
0.19
6.64%
Get RIGL Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading RIGL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    RIGL Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
8
Today's High / Low
$ 2.83 / $ 2.65
Share Volume
1,951,955
50 Day Avg. Daily Volume
2,448,428
Previous Close
$ 2.86
52 Week High / Low
$ 4.71 / $ 2.56
Market Cap
444,930,060
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.65
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.85

Intraday Chart

Shares Traded

Share Volume:
1,951,955
50 Day Avg. Daily Volume:
2,448,428

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.65

Trading Range

The current last sale of $2.67 is 4.30% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.83 $ 4.71
 Low: $ 2.65 $ 2.56

Company Description (as filed with the SEC)

Rigel Pharmaceuticals, Inc. was incorporated in Delaware in June 1996, and is based in South San Francisco, California. We are a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Our pioneering research focuses on signaling pathways that are critical to disease mechanisms. Our current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. We have a New Drug Application (NDA) under review with the FDA for fostamatinib in patients with chronic immune thrombocytopenia (ITP). In addition, we have product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.  ... More ...  


Risk Grade

Where does RIGL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.83
Open Date:
Nov. 19, 2018
Close Price:
$ 2.67
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x